Literature DB >> 2903997

Subcutaneous apomorphine for on-off oscillations in Parkinson's disease.

K R Chaudhuri, P Critchley, R J Abbott, I F Pye, P A Millac.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2903997     DOI: 10.1016/s0140-6736(88)90860-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  16 in total

Review 1.  Apomorphine and the dopamine hypothesis of schizophrenia: a dilemma?

Authors:  L Dépatie; S Lal
Journal:  J Psychiatry Neurosci       Date:  2001-05       Impact factor: 6.186

2.  The clinical use of apomorphine in Parkinson's disease.

Authors:  M J Steiger; N P Quinn; C D Marsden
Journal:  J Neurol       Date:  1992-08       Impact factor: 4.849

3.  Subcutaneous apomorphine for parkinsonian patients with psychiatric side effects on oral treatment.

Authors:  K Ray-Chaudhuri; R J Abbott; P A Millac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-04       Impact factor: 10.154

Review 4.  The modern management of Parkinson's disease.

Authors:  N Quinn
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

Review 5.  The on-off phenomenon.

Authors:  A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-06       Impact factor: 10.154

6.  Comparison of motor response to apomorphine and levodopa in Parkinson's disease.

Authors:  P A Kempster; J P Frankel; G M Stern; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-11       Impact factor: 10.154

Review 7.  [Apomorphine in the treatment of Parkinson's Disease].

Authors:  D Dressler
Journal:  Nervenarzt       Date:  2005-06       Impact factor: 1.214

8.  Subcutaneous apomorphine in the treatment of Parkinson's disease.

Authors:  J P Frankel; A J Lees; P A Kempster; G M Stern
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-02       Impact factor: 10.154

9.  Continuous subcutaneous waking day apomorphine in the long term treatment of levodopa induced interdose dyskinesias in Parkinson's disease.

Authors:  A Colzi; K Turner; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

10.  Subcutaneous apomorphine infusion in Parkinson's disease: does it have a role?

Authors:  K A Muhiddin; M T Roche; V R Pearce
Journal:  Postgrad Med J       Date:  1994-05       Impact factor: 2.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.